International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Luciano J Costa; Rahul Banerjee; Hira Mian; Katja Weisel; Susan Bal; Benjamin A Derman; Maung M Htut; Chandramouli Nagarajan; Cesar Rodriguez; Joshua Richter; Matthew J Frigault; Jing C Ye; Niels W C J van de Donk; Peter M Voorhees; Benjamin Puliafito; Nizar Bahlis; Rakesh Popat; Wee Joo Chng; P Joy Ho; Gurbakhash Kaur; Prashant Kapoor; Juan Du; Fredrik Schjesvold; Jesus Berdeja; Hermann Einsele; Adam D Cohen; Joseph Mikhael; Yelak Biru; S Vincent Rajkumar; Yi Lin; Thomas G Martin; Ajai Chari

doi:10.1038/s41375-024-02482-6

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Leukemia. 2025 Mar;39(3):543-554. doi: 10.1038/s41375-024-02482-6. Epub 2025 Jan 27.

Authors

Luciano J Costa¹, Rahul Banerjee², Hira Mian³, Katja Weisel⁴, Susan Bal⁵, Benjamin A Derman⁶, Maung M Htut⁷, Chandramouli Nagarajan⁸, Cesar Rodriguez⁹, Joshua Richter⁹, Matthew J Frigault¹⁰, Jing C Ye¹¹, Niels W C J van de Donk¹², Peter M Voorhees¹³, Benjamin Puliafito¹⁰, Nizar Bahlis¹⁴, Rakesh Popat¹⁵, Wee Joo Chng¹⁶, P Joy Ho¹⁷, Gurbakhash Kaur⁹, Prashant Kapoor¹⁸, Juan Du¹⁹, Fredrik Schjesvold²⁰, Jesus Berdeja²¹, Hermann Einsele²², Adam D Cohen²³, Joseph Mikhael^{24

25}, Yelak Biru²⁵, S Vincent Rajkumar¹⁸, Yi Lin¹⁸, Thomas G Martin²⁶, Ajai Chari²⁶

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ljcosta@uabmc.edu.
² Division of Hematology and Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA.
³ Department of Oncology, McMaster University, Hamilton, ON, Canada.
⁴ University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁵ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
⁶ Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
⁷ Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, CA, USA.
⁸ Singapore General Hospital, Singapore, Singapore.
⁹ Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA.
¹⁰ Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
¹¹ MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
¹² Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
¹³ Levine Cancer Institute, Atrium Health Wake Forest Baptist, Charlotte, NC, USA.
¹⁴ Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
¹⁵ NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁶ National University Cancer Institute, Singapore, National University Health System; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
¹⁷ Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia.
¹⁸ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
¹⁹ Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.
²⁰ Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
²¹ Greco-Hainsworth Centers for Cancer Research, Tennessee Oncology, Nashville, TN, USA.
²² Department of Internal Medicine II, University Hospital, Wurzburg, Germany.
²³ University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA.
²⁴ Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
²⁵ International Myeloma Foundation, Studio City, CA, USA.
²⁶ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

Abstract

T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.

Publication types

Review

MeSH terms

Humans
Immunotherapy* / methods
Immunotherapy, Adoptive / methods
Multiple Myeloma* / immunology
Multiple Myeloma* / therapy
Practice Guidelines as Topic* / standards